Tandem Diabetes Care (NASDAQ:TNDM) Lifted to “Hold” at StockNews.com

StockNews.com upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a sell rating to a hold rating in a report issued on Friday morning.

A number of other equities research analysts have also recently commented on the company. Stifel Nicolaus raised Tandem Diabetes Care from a hold rating to a buy rating and raised their price target for the company from $24.00 to $37.00 in a report on Tuesday, March 26th. Citigroup lifted their price target on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $37.00.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $30.43 on Friday. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -8.85 and a beta of 1.12. The stock has a fifty day moving average of $29.94 and a 200 day moving average of $24.89. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. Tandem Diabetes Care has a 52-week low of $13.82 and a 52-week high of $40.92.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million for the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. On average, research analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of TNDM. RiverPark Advisors LLC purchased a new position in Tandem Diabetes Care during the 4th quarter worth $27,000. MCF Advisors LLC raised its position in shares of Tandem Diabetes Care by 79.3% in the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares during the last quarter. State of Wyoming raised its position in shares of Tandem Diabetes Care by 45.8% in the fourth quarter. State of Wyoming now owns 821 shares of the medical device company’s stock valued at $37,000 after buying an additional 258 shares during the last quarter. Signaturefd LLC grew its holdings in Tandem Diabetes Care by 871.8% in the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 1,517 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in Tandem Diabetes Care by 51.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after purchasing an additional 1,099 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.